0.68
+6.42%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dare Bioscience
From its filings with the US Securities and Exchange Commission
Dare Bioscience is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DARE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.0m and a net loss of $13.4m. At that date it held total assets of $32.5m and shareholders' equity of $2.8m.
We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs.
For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline.
We regularly hear from healthcare providers, researchers, and women themselves about the urgent need for expanded access to evidenced-based and convenient options. Our goal is to fulfill that need by bringing innovative products to market as soon as practicable, whether as FDA-approved therapies or through alternative regulatory pathways that enable earlier availability, such as Section 503B compounding. Through a pipeline of investigational products and near-commercial, alternative pathway products, we aim to close persistent gaps in care and deliver clinically meaningful advances that redefine standards in women’s health.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 10 Apr 2014
- Employees
- 21
- Website
- darebioscience.com ↗
- Head office
- 3655 NOBEL DRIVE, SAN DIEGO, CA, 92122
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. William RastetterIndependent Chairman of the Board$91,945
- Ms. Sabrina JohnsonPresident, Chief Executive Officer, Secretary, Director, since 2017$898,382
- Ms. Mardee Haring-laytonChief Accounting Officer$513,241
- Ms. Jessica GrossmanIndependent Director$63,445
- Dr. Susan KelleyIndependent Director$59,945
- Mr. Gregory MatzIndependent Director$70,945
- Dr. Robin SteeleIndependent Director$64,445
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ovaprene offers a non-hormonal contraceptive ring with a unique permeable mesh design for sperm barrier.
- Daré Bioscience focuses on women's reproductive health with a lead product candidate in clinical stage.
- The company's product provides multiple weeks of protection without intervention during intercourse.
Weaknesses
- The company has only 15 full-time employees, indicating limited operational capacity.
- Daré Bioscience is a small firm with a single lead product candidate, Ovaprene.
- The company went public in 2014, suggesting a relatively short market presence.
Opportunities
- Ovaprene's clinical stage development could lead to commercialization in women's reproductive health market.
- The firm's focus on non-hormonal contraceptives may attract growing market demand.
- Daré Bioscience can expand its product portfolio in the women's health sector.
Threats
- The company's small size and limited employee count may hinder rapid market expansion.
- Competition in the contraceptive market could impact Ovaprene's commercial success.
- Regulatory hurdles may delay the approval and launch of Ovaprene.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.